Global Wellness Strategies Inc. (O3X.F)
Chart Events
Performance Outlook
| Previous Close | 0.0485 |
| Open | 0.0480 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's Range | 0.0480 - 0.0480 |
| 52 Week Range | 0.0060 - 0.2320 |
| Volume | |
| Avg. Volume | 1,286 |
| Market Cap | 1.133M |
| Beta (5Y Monthly) | -1.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0690 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
Global Wellness Pharma Subsidiary Supports Cancer Therapeutic Company AVM Biotechnology
Vancouver, British Columbia--(Newsfile Corp. - December 5, 2022) - Global Wellness Strategies Inc. (CSE: GWS) (FSE: O3X) (OTCQB: GWSFF) ("Global Wellness" or the "Company") pharma subsidiary is excited to work with BioMed360 a GWS medical advisor.GWS pharma subsidiary is focused on providing companies with financial, operational, and management assistance during their clinical trials phase. GWS announces that BioMed360 Solutions Corp signed a letter of intent for the 100% acquisition of AVM Biot
- Newsfile
Global Wellness Strategies Forms Pharma Subsidiary Focused on Clinical Trials
Vancouver, British Columbia--(Newsfile Corp. - November 17, 2022) - Global Wellness Strategies Inc. (CSE: GWS) (FSE: O3X) (OTCQB: GWSFF) ("Global" or the "Company") a prospect generator that provides high growth companies with financial, operational, and management assistance focused in health and wellness announces the formation of a wholly owned pharma subsidiary focused on clinical trials."Real strategic capital market partnerships are essential to assist our clients in their progression to t
- Newsfile
Global Wellness Corporate Quarter Highlights
Vancouver, British Columbia--(Newsfile Corp. - June 27, 2022) - Global Wellness Strategies Inc. (CSE: GWS) (FSE: O3X4) (OTCQB: GWSFF) ("Global" or the "Company") provides quarter corporate highlights.The Company quarter corporate highlights included announcing:May 12th that Global Wellness' Shanti Therapeutics was preparing for their first clinical trial with iNGENü a subsidiary of Australian leader Cannvalate. Shanti' s product suite of MDMA could be the global market winner finding a solution
